Dear Colleagues,

AdMeTech Foundation’s Third Global Summit on Precision Diagnosis and Treatment of Prostate Cancer took place on August 3-5 in Boston, MA. The program can be reviewed here.

The goals of establishing this new blog dedicated to the Annual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer are two-fold:

I. To provide a brief summary of the major Summit 2018 highlights, findings and recommendations from my perspective; and 

II. To ask you for your response, comments and suggestions for the 4th Global Summit, which is currently planned for October 3-5, 2019 in Boston (View flyer here)

Looking forward to your review and input,
-Faina Shtern, MD, President and CEO, AdMeTech Foundation Summit Chair and Organizer

  • EMERGING IMPORTANT TRENDS HIGHLIGHTED BY THE THIRD GLOBAL SUMMIT:                                                             ADMETECH’S PERSPECTIVE FOR YOUR REVIEW AND INPUT

  1. Radiogenomics, or integrated, multi-modality, comprehensive approach to precision diagnosis and its impact on precision care.

  2. Rapidly expanding discovery of new genetic and molecular targets for both early and advanced prostate cancer (PC), which are critical for further development and integration of in vitro diagnostics, molecular imaging and dedicated drugs.

  3. Impact of precision diagnosis on treatment design, administration and monitoring, including recurrent and advanced prostate cancer.

  4. Validated PSA isomers (e.g., phi or 4K Score) and novel liquid biomarkers (e.g., germline testing) and their integration with imaging, especially multi-parametric (mp) MR for improved selection of patients for biopsy. During the Brain Trust, there was an intense debate which modality should come first (liquid biomarkers vs. mpMRI), and it has become clear this debate should be resolved through the related research and data rather than consensus.

  5. Fusion of Transrectal Ultrasound (TRUS) with mpMRI for improved biopsy tissue sampling  for routine pathologic assessment (e.g., Gleason Pattern/Score) and genetic tissue profiling. Based on a preliminary data, high-resolution micro-ultrasound appears to be a significant improvement compared to a standard TRUS – and is likely to impact clinical value of MRI/US Fusion Guidance.

  6. Multiple promising in vitro novel liquid and tissue biomarkers and in vivo imaging tools have emerged recently for improved assessment of early and advanced prostate cancer that require further research.

  7. Further expert consensus and research is needed to define clinical indications for adding:

    a. Genetic cancer profiling to routine pathologic examination of biopsy tissue samples, with the goal to improve patient selection for precision care (e.g., Active Surveillance, Focal Interventions/”Male Lumpectomy”, or Immediate Whole Gland Treatment); and

    b. Genetic cancer profiling to routine pathologic examination of post-surgical tissue specimens, with the goal to optimize treatment planning.

  8. Machine Learning and related tools for multi-factorial, multi-modality data analysis.

  9. Several areas of imaging, including:

    a. mpMRI is currently the most promising and validated imaging tool before and after diagnosis of PC. However, the need for broader standardization of image acquisition, quality and interpretation has been recognized; and

    b. Transition of molecular imaging (and related fusion with anatomic imaging, such as MRI or CT) from diagnostic use only for advanced PC (discussed at the First and Second Global Summit) to early diagnosis of recurrence and biologic characterization of the early stages of localized disease;

  10. Image-Guided Focal Treatment emerged as a promising, credible additional option to Active Surveillance and Immediate Whole-Gland Treatment .  

 

PLEASE ADDRESS THE FOLLOWING 5 QUESTIONS TO HELP US SHAPE THE NEXT GLOBAL SUMMIT IN 2019: